Fenofibrate

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Fenofibrate and local guidelines before prescribing.

Fibrate

Mechanism

PPAR-alpha agonist.

Uses

Hypertriglyceridaemia, mixed dyslipidaemia, diabetic retinopathy (selected).

Dosing

No dose is given in the chapters. See the BNF.

Side effects

GI upset, myopathy, raised creatinine, gallstones.

Interactions

Statins increase myopathy; warfarin effect rises.

Contraindications and cautions

Severe renal or liver impairment, gallbladder disease

Monitoring

Lipids, LFT, CK if symptoms

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

Avoid in moderate to severe renal impairment

Overdose and reversal

Supportive

Special advice

Check creatinine; not first-line for LDL.

More from the textbook: uses, cautions and other points
Where it is discussed in the book